✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Exit Type◇ research
Unknown
Subsequent Funding◇ research
$13,350,000
Received VC Funding◇ research
Yes
Current Employees◇ research
—
Peak Employees◇ research
—
SBIR/STTR Awards◇ research
—
Filed Form D◇ research
Yes
Used Crowdfunding◇ research
—
Notes
KAITC records show $125,000 actual angel investment in 2017. SEC Form D shows $650,000 sold in a 2016 offering; Liberate announced a $6.2 million Series B in 2023 and a $6.5 million DoD-funded PREVENT study in 2024. Company site remains active in 2026 from Crestwood, KY.
[Deep research 2026-04-11] Company remains active as of April 2024 with headquarters at 6400 Westwind Way, Suite A, Crestwood, KY 40014. Leadership team includes CEO Angus McLachlan and co-founder Cedric Francois. VentFree device has FDA Breakthrough Device Designation (2019), CE marking (2019), and FDA Emergency Use Authorization (2020). PREVENT pivotal trial launched April 2024 targeting 272 patients across 25 global centers.
Last updated: Apr 11, 2026 · Evidence score: 5/5